June 23, 2024

U.S. Scrutiny of Chinese Company Could Disrupt U.S. Supply Chain for Key Drugs

Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is deeply involved in development and manufacturing of crucial therapies for cancer, cystic fibrosis, H.I.V. and other illnesses.Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is deeply involved in development and manufacturing of crucial therapies for cancer, cystic fibrosis, H.I.V. and other illnesses.Read MoreUnited States International Relations, Drugs (Pharmaceuticals), Factories and Manufacturing, United States Politics and Government, Biotechnology and Bioengineering, Cystic Fibrosis, Cancer, Supply Chain, Intellectual Property, Shortages, Government Contracts and Procurement, Labor and Jobs, Start-ups, Leukemia, Research, Tax Credits, Deductions and Exemptions, AbbVie Inc, Eli Lilly and Company, GlaxoSmithKline PLC, House of Representatives, Janssen Pharmaceutica, People’s Liberation Army (China), Senate, WuXi PharmaTech, China, Delaware, MassachusettsNYT > Health

Leave a Reply

Your email address will not be published. Required fields are marked *